Tag Archives: finance

Hot Investor Mandate: Family-Office Backed Investment Vehicle Seeks Innovative Medtech Opportunities in US, Western Europe, and Asia

10 Mar

The firm is a joint venture investment vehicle established by a family office and a strategic investment partner. The firm focuses on later-stage medical device opportunities, particularly Series A and Series B companies approaching regulatory approval. The firm primarily evaluates opportunities in the United States and Western Europe, while remaining open to select companies based in Asia. Typical check sizes range from approximately $500K to $1.5M, and the firm prefers to lead transactions. The firm may also co-invest alongside affiliated investment vehicles to support later-stage, revenue-generating companies that demonstrate a clear path to exit within a relatively short time horizon. Through long-standing industry relationships, the firm helps introduce portfolio companies into a specialized medical technology ecosystem to accelerate growth and commercialization.  

The firm evaluates opportunities across medical device categories but maintains a strong focus on implantable technologies. Core areas of interest include neuromuscular and musculoskeletal indications, particularly orthopedic and spine implants. The firm also reviews opportunities in cardiology, vascular and peripheral devices, surgical technologies, and select oncology-related technologies. Companies should typically be approaching regulatory approval and demonstrate validated technology and clinical utility.  

From a company and management team perspective, the firm requires board representation and at minimum takes an observer seat in portfolio companies. The firm seeks companies with proven technology, clear regulatory pathways, and strong commercial potential within established clinical markets. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

RESI Europe 2026 Investor Panels Take the Stage in Lisbon 

3 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is preparing for RESI Europe 2026, taking place March 23 in person at the EPIC SANA Lisboa Hotel, followed by four days of virtual partnering. 

The RESI Europe panel program will bring together active healthcare investors to discuss the sectors and strategies shaping early-stage capital formation across therapeutics, devices, diagnostics, digital health, and enabling technologies. As European companies increasingly look beyond domestic markets for capital, the conversations will reflect cross-border investment dynamics and milestone expectations in today’s disciplined funding environment. 

These panels are structured as constructive dialogue between investors and fundraising CEOs. Attendees will hear directly from venture, corporate, and strategic investors about how opportunities are evaluated, what readiness looks like at Seed and Series A, and how companies can engage the right partnering environments at the right time. 

Join the panelists at RESI Europe 2026 and engage directly with the investors shaping early-stage healthcare capital. 

Special Offer: Register for a RESI Europe 5-day hybrid ticket and receive a complimentary second attendee pass. This promotion applies to standard hybrid registrations and provides an opportunity to bring a colleague to maximize partnering coverage across all five days. 

Register for RESI Europe and secure meetings with active healthcare investors in Lisbon this March. 

Register for RESI Europe
RESI Europe Investor Panel Speakers
Raj-Airey
Raj Airey
Convergence Partners AG		 Rosie-Barnett
Rosie Barnett
Delin Ventures		 Amine-Benmoussa
Amine Benmoussa
Karista
Marcos-Casado
Marcos Casado
Invivo Partners		 Bettina-Ernst
Bettina Ernst
BERNINA BioInvest		 Navin-Govind-
Navin Govind
Evidence Ventures

William Hsu
Life Science Angels		 Mohammad-Khobreh
Mohammad Khobreh
NG Bio		 Carsten-Laue
Carsten Laue
M2Care
Chloe-Lepretre
Chloé Lepretre
Servier		 Mukul-Mohanty
Mukul Mohanty
Truffle Capital		 Luka-Nicin
Luka Nicin
Pace Ventures
Joseph-Oliver
Joseph Oliver
Stanford Angels of the UK		 Soyoung-Park
Soyoung Park
1004 Venture Partners		 Francisco-Pinto
Francisco Pinto
Bynd Venture Capital
Bibi-Sattar-Marques
Bibi Sattar Marques
Buenavista Equity Partners		 Jeff-Stinson
Jeff Stinson
HTA		 Mercedes-Tuin
Mercedes Tuin
Heran Partners
Carmel-van-den-Berk
Carmel van den Berk
Brightlands Venture Partners		 Mariette-van-der-Velden
Mariette van der Velden
Curie Capital		 Giulia-Vestri
Giulia Vestri
Claris Ventures
Yu-Zhang
Yu Zhang
FaaS Capital

Tags: , , , , , , , , , , , ,

EU Webinar Series: From Discovery to Decision Making Early-Stage Life Science Legible to Capital 

3 Mar

By Greg Mannix, VP, EMEA Business Development, LSN

Life Science Nation’s EU-focused webinar series, From Discovery to Decision: Making Early-Stage Life Science Legible to Capital, continues this week with Session III. Recordings of the first two sessions are available for those who would like to revisit the insights shared by active investors shaping early-stage healthcare financing.

This series examines a central question for early-stage companies: why strong science alone is not enough to secure capital, and how founders can structure development to become legible to investors.

Session I

Why Solid Science Fails to Translate Before Capital Even Considers It

Hosted by Richard Berenson, Managing Partner, Venzyme Catalyst

Watch the recording:
https://youtu.be/ODbukG6cjNM?si=9lj-BGKRhv2wJISW

In Session I, Richard Berenson offered a candid investor perspective on why many early-stage assets stall before diligence begins. He emphasized that the issue is often not a shortage of capital, but a failure of translation.

Scientific merit alone does not make an opportunity investable. Investors must see clarity around risk reduction, defined milestones, regulatory trajectory, and capital deployment strategy. Companies that struggle to articulate this framework may be filtered out long before meaningful evaluation takes place.

The discussion reframed from fundraising challenges as structural alignment issues rather than capital scarcity.

Session II

Legibility, Signal, and the Real Work Between Seed and Series B

Hosted by Karim Galzhar, Partner, OKG Capital

Watch the recording:
https://youtu.be/Dak112sslq4?si=9MpLvecop5Jxw4_E

Session II built on this foundation with a deeper examination of how investors form conviction between Seed and Series B.

Karim Galzhar outlined what global investors require to underwrite early-stage risk. Signals are formed across scientific validation, regulatory planning, commercial strategy, and disciplined capital use. Data alone does not create signals. Structured progress and stage-appropriate positioning.

The session highlighted how companies can unintentionally dilute signals by engaging the wrong forums too early or by misaligning fundraising expectations with development readiness.

Session III — This Wednesday

Partnering Is Not Exposure. It Is Filtration

Wednesday, March 4 | 10:00 AM ET / 4:00 PM CET

Session III will feature Dennis Ford, Founder & CEO of Life Science Nation and creator of the RESI Conference Series, alongside Gregory Mannix, VP, International Business Development, Life Science Nation.

This session confronts a simple truth: great science does not raise capital, signal does. We will examine how investors actually price risk, why fundraising must be run as a disciplined global campaign, and how legibility turns complex science into an investable story.

We will also address a costly mistake: engaging the wrong partnering events and the wrong investors too early. Not every conference, forum, or investor fits every stage of development. Success requires selecting the right venues, building a stage-appropriate global target list, and engaging partners who are structurally aligned with your product. The goal is to replace activity with real transaction momentum.

Registration for Session III is open: https://us02web.zoom.us/webinar/register/WN_oe499TEOQGmrSnoAzNr1yw#/registration

Register for RESI Europe

Tags: , , , , , , , , , ,

Hot Investor Mandate: Family Office Backed Firm Seeks to Invest in Therapeutics, Especially Rare Diseases and Areas of Unmet Medical Need

3 Mar

The firm is a family-run investment and commercialization vehicle focused on early-stage life sciences and technology opportunities. The firm is flexible in structuring transactions, with prior investments ranging from minority participation in financing rounds to in-licensing entire therapeutic programs.  

The firm specializes in therapeutic opportunities, with a particular emphasis on rare diseases. The firm prioritizes indications where the pathophysiology is well understood, the development pathway is straightforward, and there is a clearly defined unmet medical need. The firm is also attracted to opportunities that are de-risked, including reformulation strategies and drug repurposing approaches.  

From a company and management team perspective, the firm has a strong preference for experienced leadership teams with proven track records of value creation and execution.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Family Office Invests in Pre-Clinical and Clinical Stage Biotech and Tech-Enabled Healthcare Technologies in North America

3 Mar

A family office invests in both private and public life science and healthcare companies. The firm typically writes six-figure checks for companies approaching clinical development. While historically focused on North America, the firm remains open to evaluating opportunities globally. The firm invests across therapeutics, diagnostics, digital health, and medical devices.  

The firm is generally disease-agnostic, with particular interest in ophthalmology, inflammation, and dermatology. The firm is also increasingly exploring opportunities at the intersection of technology and healthcare, including AI-enabled platforms that enhance patient management and diagnostic workflows. Although oncology is not a core focus, the firm may selectively evaluate certain indications.  

From a stage perspective, the firm reviews opportunities as early as pre-IND and generally prefers programs through Phase II development. The firm seeks evidence of technical and regulatory de-risking, including proof-of-concept data, early efficacy signals, and clearly defined regulatory pathways.  

The firm does not impose strict requirements on company or management team composition but values teams that demonstrate regulatory expertise and the ability to execute within clinical and compliance-driven environments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Global Biopharmaceutical Seeks Strategic Investment and Partnering Opportunities With Early-Stage Therapeutics Assets

3 Mar

The firm is a publicly listed global biopharmaceutical company headquartered in Asia with a strong presence across major international markets. The firm is recognized for its capabilities in large-scale biologics development and manufacturing and has built a substantial commercial footprint worldwide. The firm pursues external innovation through equity investments, research collaborations, and in-licensing arrangements to strengthen and diversify its pipeline.  

The firm operates broadly across therapeutics and biopharmaceutical innovation, with established expertise in antibody-based medicines, follow-on biologics, and next-generation biologic platforms. The firm continues to expand into novel therapeutic programs across immunology, oncology, infectious diseases, and other high-need areas. In addition to maintaining a portfolio of established biologic products, the firm is actively enhancing its innovative pipeline through internal research, strategic partnerships, and selective in-licensing of differentiated biologic assets, including immune-modulating therapies and advanced antibody formats. The firm is open to opportunities across development stages, with interest in early and mid-stage programs.  

The firm seeks partnerships that align with its long-term biologics strategy and leverage its global development, regulatory, and manufacturing infrastructure. The firm evaluates opportunities based on strong scientific rationale, differentiated clinical positioning, scalable manufacturing feasibility, and global market potential. The firm prefers to collaborate with teams that demonstrate rigorous data generation, defensible intellectual property, and the operational capability to execute international development and commercialization strategies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Cross-Border VC Firm With New Early-Stage Fund Invests in Biotech, Medtech, and Enabling Platforms in North America and Asia

3 Mar

 
 The firm is a global venture capital firm headquartered in Asia, with investment activity spanning Asia and the United States. The firm has raised multiple funds and recently launched a dedicated vehicle focused on biotechnology and medical technology innovation. The firm invests from Seed through early-growth stages and has backed a broad portfolio of healthcare companies. The firm deploys equity capital and works closely with founders to support global expansion, leveraging cross-border operating presence and networks across Asia and North America.  

The firm focuses on biotechnology, medical technology, and enabling platforms addressing major unmet needs in human health. The firm invests in breakthrough science and engineering-driven innovation, including therapeutics, medtech devices, diagnostics, digital health, research tools, and frontier health technologies. The firm follows a cross-border strategy that sources scientific breakthroughs from both Eastern and Western ecosystems, particularly opportunities facing market fragmentation or structural barriers that may limit global scale. The firm emphasizes companies with strong scientific foundations, differentiated clinical or technical positioning, and opportunities that can benefit from accelerated development and market access through Asian clinical, talent, and supply chain ecosystems.  

From a company and management team perspective, the firm partners with founders who demonstrate deep scientific or medical expertise, strong execution capability, and readiness for global expansion. The firm actively supports teams through hands-on venture building and provides access to clinical resources, supply networks, operating talent, and cross-border strategic guidance. The firm collaborates with companies from early stages through exit, aligning with founders to pursue global outcomes including IPOs, M&A, and strategic partnerships. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries
Newer Entries →